# A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)

> **NCT06464588** · PHASE1 · RECRUITING · sponsor: **Emory University** · enrollment: 36 (estimated)

## Conditions studied

- Dilated Cardiomyopathy

## Interventions

- **BIOLOGICAL:** Allogeneic Neonatal mesenchymal stromal cells (nMSCs)

## Key facts

- **NCT ID:** NCT06464588
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-14
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06464588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06464588, "A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06464588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*